rabeximod
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2007 (NCT00525213)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetUnclear
Unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 9-chloro-2,3-dimethyl-6-(n,n-dimetylamino-2-oxoethyl)-6h-indolo(2,3-b)quinoxaline
- rabeximod
- rob 803
- rob 803
- rob 803
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00525213 | Phase 2 | Oct 1, 2007 | Karolinska Institute, OxyPharma |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Karolinska Institute | Academic/Hospital | 1 | 0 | 1 | 2007 |
| OxyPharma | For profit | 1 | 1 | 1 | 2007 |
2 organizations
Page 1 / 1